Salud femenina

A continuación se enumeran ensayos clínicos actuales.

107 estudios en Salud femenina
(estudios abiertos únicamente).

Filtrar esta lista de estudios según la ubicación, el estado del estudio y más.

1. Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

   Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   This phase II trial studies how well Avatar-directed chemotherapy works in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that does not respond to platinum anti-cancer drugs. Drugs used in chemotherapy, such as paclitaxel, gemcitabine hydrochloride, pegylated liposomal doxorubicin hydrochloride, topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Using an Avatar, a living tumor sample with similar genetic characteristics to the original tumor, may help determine which chemotherapy is most effective.

2. Lobular Involution-Based Response to Antiendocrine Therapy for Women with Breast Atypical Hyperplasia

   Jacksonville, Fla.

   The goal of this study is to perform a quantitative measure of lobular involution (qLI) from breast biopsy samples obtained at baseline (surgery) and 12 months or at time of study discontinuation. The study will determine breast density (MMG) and correlate with qLI. The study will also determine the influence of chemoprevention therapies such as tamoxifen and letrozole on qLI.

3. A Study to Evaluate Olaparib and Temozolomide in Treating Patients With Advanced, Metastatic, or Unresectable Uterine Leiomyosarcoma

   Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.

   The purpose of this study is to evaluate olaparib and temozolomide in treating patients with uterine leiomyosarcoma (LMS) that has spread to other places of the body or cannot be removed by surgery. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving olaparib and temozolomide may work better than giving either drug alone in treating patients with LMS.

4. A Study of Pembrolizumab in Treating Participants with Recurrent Ovarian Cancer

   Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   The purpose of this study is to evaluate how well pembrolizumab works in treating participants with ovarian cancer that has come back after previous treatment. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.

5. A Study to Evaluate Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

   Scottsdale/Phoenix, Ariz., Rochester, Minn.

   The purpose of this study is to evaluate the effects and best dose of atezolizumab when given together with guadecitabine and CDX-1401 vaccine and to see how well they work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. CDX-1401 vaccine may enhance the expression of the genes encoding tumor antigens on the surface of tumor cells and enhance the activity of tumor-killing T cells against those tumor cells. Vaccines made from monoclonal antibodies combined with tumor cells may help the body build an effective immune response to kill tumor cells. Giving atezolizumab, guadecitabine, and CDX-1401 vaccine may work better than CDX-1401 alone in treating patients with ovarian, fallopian tube, or primary peritoneal cancer.

6. A Study of to Evaluate Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer

   Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.

   The purpose of this study is to evaluate combining endocrine therapy with CDK4/6 inhibition along with trastuzumab in ER+/ human epidermal growth factor receptor 2 (HER2)+ early stage breast cancer in order to influence estrogen receptor (ER) signaling.

7. A Study to Compare the Feasibility and Effectiveness of SHUT-I vs. Standard Care for Insomnia Management in Fibromyalgia Patients

   Rochester, Minn.

   The purpose of this study is to gather preliminary data on feasibility and effectiveness of cognitive behavior therapy (SHUT-I) versus traditional sleep hygiene education on insomnia in patients with fibromyalgia.

8. A Study to Assess Reproductive History in Kidney Donors

   Rochester, Minn., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to analyze the effect of parity, menopause and reproductive lifespan on kidney structure and function.

9. A Study to Evaluate Patient Perspectives of Vaginal Bleeding During the Menopause Transition and Future Innovations Addressing Changes in Vaginal Bleeding Patterns

   Jacksonville, Fla.

   The primary purpose of this study is to assess how women within different stages of menopause perceive menstrual bleeding changes during the menopause transition within the outpatient gynecology practice.

    

10. Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women

    Rochester, Minn.

    The purpose of this two-part study is to evaluate the effect of 15 or 20 mg of Estetrol (E4), or placebo, on the severity and frequency of vasomotor symptoms (VMS) (Efficacy Study Part) and the safety of E4 20 mg (Safety Study Part) in postmenopausal women.